University of Tennessee Health Science Center Campus Photos
OWA WebMail  /  SiteMap  /  Contact Information

Division Faculty


Marshall B. Elam, MD, PhD

Title:
Associate Professor of Pharmacology and Medicine
Chief, Division of Clinical Pharmacology, VAMC

Contact Information:
Email:  melam@uthsc.edu
Office:  (901) 448-6011

Clinical/ Research Interest
Atherosclerosis and lipoprotein metabolism, regulation of apolipoprotein B synthesis and apoB mRNA editing by insulin, and pharmacologic interventions in patients with cholesterol disorders.  He is also studying the role of homocysteine and DHEA in atherosclerosis.

Residency:  University of Tennessee
Fellowship:  University of Tennessee
Joined UT:  1985

Recent Publications:

1.    Egan DA, Garg R, Wilt TJ, Pettinger MB, Davis KB, Crouse J, Herd JA, Hunninghake DB, Sheps DS, Kostis JB, Probstfield J, Waclawiw MA, Applegate W, Elam MB. Rationale and design of the Arterial Disease Multiple Intervention Trial (ADMIT) pilot study. Am J Cardiol 1999;83:569-575.

2.    Elam MB, von Wronski MA, Cagen L, Thorngate F, Kumar P, Heimberg M, Wilcox HG. Apolipoprotein B mRNA editing and apolipoprotein gene expression in the liver of hyperinsulinemic fatty Zucker rats: relationship to very low density lipoprotein composition. Lipids 1999;34:809-816.

3.    Elam MB, Hunninghake DB, Davis KB, Garg R, Johnson C, Egan D, Kostis JB, Sheps DS, Brinton EA. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000;284:1263-1270.

4.    Pahor M, Elam MB, Garrison RJ, Kritchevsky SB, Applegate WB. Emerging noninvasive biochemical measures to predict cardiovascular risk. Arch Intern Med 1999;159:237-245.

5.    Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-418.